1. Home
  2. ABTS vs KZIA Comparison

ABTS vs KZIA Comparison

Compare ABTS & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABTS
  • KZIA
  • Stock Information
  • Founded
  • ABTS 2010
  • KZIA 1994
  • Country
  • ABTS Hong Kong
  • KZIA Australia
  • Employees
  • ABTS N/A
  • KZIA N/A
  • Industry
  • ABTS Computer Software: Programming Data Processing
  • KZIA Biotechnology: Pharmaceutical Preparations
  • Sector
  • ABTS Technology
  • KZIA Health Care
  • Exchange
  • ABTS Nasdaq
  • KZIA Nasdaq
  • Market Cap
  • ABTS 14.3M
  • KZIA 12.6M
  • IPO Year
  • ABTS N/A
  • KZIA 1999
  • Fundamental
  • Price
  • ABTS $0.47
  • KZIA $0.44
  • Analyst Decision
  • ABTS
  • KZIA Strong Buy
  • Analyst Count
  • ABTS 0
  • KZIA 1
  • Target Price
  • ABTS N/A
  • KZIA $2.00
  • AVG Volume (30 Days)
  • ABTS 35.6K
  • KZIA 1.7M
  • Earning Date
  • ABTS 11-27-2024
  • KZIA 10-08-2024
  • Dividend Yield
  • ABTS N/A
  • KZIA N/A
  • EPS Growth
  • ABTS N/A
  • KZIA N/A
  • EPS
  • ABTS N/A
  • KZIA N/A
  • Revenue
  • ABTS $5,343,888.00
  • KZIA $382.00
  • Revenue This Year
  • ABTS N/A
  • KZIA $4,053,954.00
  • Revenue Next Year
  • ABTS N/A
  • KZIA N/A
  • P/E Ratio
  • ABTS N/A
  • KZIA N/A
  • Revenue Growth
  • ABTS 3970.67
  • KZIA N/A
  • 52 Week Low
  • ABTS $0.38
  • KZIA $0.19
  • 52 Week High
  • ABTS $1.60
  • KZIA $1.58
  • Technical
  • Relative Strength Index (RSI)
  • ABTS 44.67
  • KZIA 62.71
  • Support Level
  • ABTS $0.43
  • KZIA $0.38
  • Resistance Level
  • ABTS $0.53
  • KZIA $0.51
  • Average True Range (ATR)
  • ABTS 0.04
  • KZIA 0.03
  • MACD
  • ABTS -0.00
  • KZIA 0.01
  • Stochastic Oscillator
  • ABTS 36.36
  • KZIA 65.10

About ABTS Abits Group Inc

Abits Group Inc is a digital data center operator with bitcoin self-mining operations.

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.

Share on Social Networks: